Prometic Gets FDA Nod to Initiate Phase 2/3 Trial of PBI-4050 Combined with Ofev in IPF Patients
A Phase 2/3 clinical trial of PBI-4050, a potential new therapy for idiopathic pulmonary fibrosis (IPF), has been approved by the U.S. Food and Drug Administration (FDA), according to Prometic Life Sciences. The FDA has granted the drug candidate investigational new drug (IND) status, which facilitates clinical research. The Phase 2/3…